Showing 2501-2510 of 4166 results for "".
- Bausch + Lomb Will Present Scientific and Clinical Research During ARVO Meeinghttps://modernod.com/news/bausch-lomb-will-present-scientific-and-clinical-research-during-arvo-meeing/2480199/Bausch + Lomb announced that nearly a dozen scientific posters will address the results of studies featuring several of the company’s current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision
- New Analysis From N-MOmentum Clinical Trial of Uplinza Demonstrate Process that Could Improve Clinical Care Process for NMOSDhttps://modernod.com/news/new-analysis-from-n-momentum-clinical-trial-of-uplinza-demonstrate-process-that-could-improve-clinical-care-process-for-nmosd/2481680/Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of Uplinza demonstrating the utility of an adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consiste
- Visual Clinic’s Patient Flow Management Solution Aims to Help Eye Care Clinics Operate Post-COVID-19https://modernod.com/news/visual-clinics-patient-flow-management-solution-aims-to-help-eye-care-clinics-operate-post-covid-19/2477935/Visual Clinic is offering a solution designed to help eye care clinics achieve better patient flow. The software aims to help practices run at peak efficiency, improve the patient experience, maximize practice resources, and keep overhead costs low while optimizing revenue. Additionally
- RetinAI Launches Discovery Platform for Ophthalmology and Optometry Clinicshttps://modernod.com/news/retinai-discovery-platform-launched-to-improve-workflows-referrals-and-patient-management-in-ophthalmology-and-optometry-clinics/2482122/Ikerian, the parent company of RetinAI, announced the launch of 'RetinAI Discovery for Clinics,' which features AI models designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions, and patient manage
- Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-to-enter-clinic-with-treatment-for-dry-amd/2481974/Inflammasome Therapeutics, developer of a new class of inflammasome inhibitor drugs called Kamuvudines, announced the FDA has granted approval for the opening of a phase 1/2 clinical trial of the company’s drug for the treatment of geographic atrophy (GA). This is the first clinical tr
- Rayner Launches ‘Peer2Peer: The Podcast’ for Clinical Educationhttps://modernod.com/news/rayner-launches-peer2peer-the-podcast-for-clinical-education/2481342/Rayner announced the launch of the latest addition to their Peer2Peer clinical education platform, "Peer2Peer: The Podcast." Topics included in the podcase include the do's and don’ts of implanting toric IOLs; marketing your clinic online; popular
- First Clinical Uses of Medineering Robotic Endoscopyhttps://modernod.com/news/first-clinical-uses-of-medineering-robotic-endoscopy/2480207/Medineering, a Munich, Germany-based surgical robotics company, announced the first clinical uses of its robotic Medineering Robotic Endoscopy. After having received the CE approval for the Endoscope Robot in February, various clinical uses in university hospitals across Germany (Tübingen, Ulm, R
- Ocuphire Pharma Receives FDA Agreement for Phase 3 Trial of Phentolamine Solution for Poor Night Visionhttps://modernod.com/news/ocuphire-pharma-receives-fda-agreement-for-phase-3-trial-of-phentolamine-solution-for-the-treatment-of-decreased-visual-acuity-under-dim-light-conditions/2482041/Ocuphire Pharma announced it has received agreement from the FDA under a special protocol assessment (SPA) for the clinical trial protocol and planned statistical analysis of the LYNX-2 phase 3 trial to evaluate phentolamine ophthalmic solution for the proposed indication for the treatm
- LumiThera Presents New Data from LIGHTSITE III Trial Showing Improvement in Vision in Intermediate Dry AMDhttps://modernod.com/news/lumithera-presents-new-data-from-lightsite-iii-trial-showing-improvement-in-vision-in-intermediate-dry-amd/2480930/LumiThera announced detailed findings in its LIGHTSITE III, multicenter clinical trial in non-neovascular age-related macular degeneration (AMD) subjects treated with photobiomodulation (PBM) using the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked,
- ForeseeHome AMD Home Monitoring Real-World Data Analysis Demonstrates Substantial Benefit for Patients’ Visionhttps://modernod.com/news/foreseehome-amd-home-monitoring-real-world-data-analysis-demonstrates-substantial-benefit-for-patients-vision/2479053/Real-world data on the performance of the ForeseeHome AMD Monitoring Program, a home-based diagnostic that helps detect the conversion from intermediate dry to wet age-related macular degeneration (AMD), was recently published in the Journal of Clinical Medicine as part of the “Diagnosis,